2022 Fall Conference | C12 - Neurology Update 5: Neuro-ophthalmology and Neurotoxicology

Date Saturday 10/29/22

Time 08:00 AM - 09:30 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Laurie Gutmann, MD, FAAN

Topic(s) General Neurology, Neuro-ophthalmology/Neuro-otology

Learning Objectives Neuro-ophthalmology: Participants should be able to differentiate among the many pathophysiologies that can affect the optic nerve; understand the contribution of new technologies and clinical trial results to the field of neuro-ophthalmology; and appreciate that the neuro-ophthalmologic examination and findings are windows into understanding the brain and neurology.
Neurotoxicology: Participants should have a clear understanding of how to diagnose and treat neurological disorders that may accompany illicit drug use and heavy metal toxicity; recognize the neurotoxicity associated with newer pharmaceuticals like chimeric antigen receptor T-cell therapy and therapy with immune checkpoint inhibitors; be familiar with toxidromes like serotonin syndrome, neuroleptic malignant syndrome, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome; and recognize neurotoxicity associated with cyanide, carbon monoxide, and certain bacterial and animal toxins.

CME Available 1.50 CME credits

Core Competencies Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Program Materials

Event Timeline
08:00 AM - 08:45 AM PDT	Speaker	Neuro-ophthalmology Nancy J. Newman, MD, FAAN
08:45 AM - 09:30 AM PDT	Speaker	Neurotoxicology Neeraj Kumar, MD

Faculty Disclosures
Laurie Gutmann, MD, FAAN	Dr. Gutmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Gutmann has received research support from NIH. The institution of Dr. Gutmann has received research support from Dyne Therapeutics. Dr. Gutmann has received publishing royalties from a publication relating to health care.
Nancy J. Newman, MD, FAAN	Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Phelcom. The institution of Dr. Newman has received research support from GenSight. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care.
Neeraj Kumar, MD	Dr. Kumar has nothing to disclose.

��ɫ��

��ɫ��